Photo by ajari from unsplash
The combination of atezolizumab and bevacizumab (AtezoBev) is the current first‐line treatment for patients with hepatocellular carcinoma (HCC). Our aim was to evaluate the prognostic role of alpha‐foetoprotein (AFP) early… Click to show full abstract
The combination of atezolizumab and bevacizumab (AtezoBev) is the current first‐line treatment for patients with hepatocellular carcinoma (HCC). Our aim was to evaluate the prognostic role of alpha‐foetoprotein (AFP) early response and its combination with albumin–bilirubin (ALBI) in these patients.
Keywords:
baseline albi;
early variation;
score early;
atezolizumab bevacizumab;
albi score;
albi
Journal Title: Liver International
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Liver International
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!